The University of Oxford has begun a phase one clinical trial of a nasal spray formulation of its AstraZeneca-partnered COVID-19 vaccine. Investigators plan to enroll up to 30 adults aged 18 to 40 years in the study. Half of the participants will receive a single dose, with the others getting a booster dose 28 days later. Source: Fierce Biotech 26/3/2021